Reportlinker Adds Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market

Aug 31, 2010, 11:43 ET from Reportlinker

NEW YORK, Aug. 31 /PRNewswire/ Reportlinker.com announces that a new market research report is available in its catalogue:

http://www.reportlinker.com/p0286298/Mens-Health-Therapeutics-Market-to-2016---Selective-Serotonin-Reuptake-Inhibitors-Hormone-Replacement-Therapy-and-Phosphodiesterase-Type-5-Inhibitors-Will-Dominate-the-Market.html

Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors Will Dominate the Market

Summary

GBI Research has released its pharmaceutical industry research "Men's Health Therapeutics Market to 2016 - Selective Serotonin Reuptake Inhibitors, Hormone Replacement Therapy and Phosphodiesterase Type-5 Inhibitors will Dominate the Market". The report provides in-depth analysis of unmet needs, drivers and barriers that impact the global men's health market. The report analyzes the markets for men's health in the US, the top five countries in Europe (the UK, Germany, France, Italy and Spain) and Japan. Treatment usage patterns, sales, prices and volumes are forecast until 2016 for the key geographies as well as the leading therapeutic segments. Furthermore, the report provides competitive benchmarking for the leading companies and analyzes the mergers, acquisitions and licensing agreements that shape the global markets.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GBI Research's team of industry experts.

GBI Research finds that the men's health market will continue to grow moderately. The prime reason for stagnancy will be the patent expiry of a top selling blockbuster, Viagra. The overall men's health market is driven by the launch of late-stage pipeline candidates and the steady increase in prevalence and prescription population. The erectile dysfunction market controls a major portion of the men's health market. In 2009 it accounted for 81% of the total men's health market. Male hypogonadism accounts for 18% of the total market size. The premature ejaculation market represents a small portion of the total men's health market. The premature ejaculation market has the highest level of unmet needs because it does not have any FDA approved products. However, it will grow at a higher rate during the forecast period compared to the erectile dysfunction and male hypogonadism market. This is because the premature ejaculation market will see the launch of new drugs in the near future. In 2009, the global men's health market was estimated at $4,019m.

Scope

- Annualized market data for the men's health market from 2001 to 2009, forecast forward to 2016.

- Analysis of the leading therapeutic segments, including erectile dysfunction, male hypogonadism and premature ejaculation.

- Analysis of the men's health market in the leading geographies of the world, which include the US (United States), the UK (United Kingdom), Germany, France, Italy, Spain and Japan.

- Market characterization of the men's health market, including market size, annual cost of therapy, sales volume and treatment usage patterns.

- Key drivers and barriers that have a significant impact on the market.

- Coverage of pipeline molecules in various phases of drug development.

- Competitive benchmarking of leading companies. The key companies studied in this report are Pfizer Inc., Eli Lilly and Company, GlaxoSmithKline Inc., Abbott Laboratories, Endo-Pharmaceuticals Holding Inc., Janssen-Cilag EMEA, VIVUS Inc., Auxilium Pharmaceuticals, Inc., APP Pharmaceuticals, Inc, Columbia Laboratories, Inc., Watson Pharmaceuticals, Inc. and Valeant Pharmaceuticals International.

- Key M&A activities, licensing agreements, that have taken place in 2009 in the global men's health market.

Reasons to buy

The report will enhance your decision making capability. It will allow you to

- Align your product portfolio to the markets with high growth potential.

- Develop market-entry and market expansion strategies by identifying the leading therapeutic segments and geographic markets poised for strong growth.

- Reinforce R&D pipelines by identifying new target mechanisms which can produce first-in-class molecules with more efficiency and better safety.

- Develop key strategic initiatives by understanding the key focus areas of leading companies.

- Exploit in-licensing and out-licensing opportunities by identifying products that could fill portfolio gaps.

1 Table of Contents 3

1.1 List of Tables 6

1.2 List of Figures 9

2 Global Men's Health Therapeutics Market: Scope of Research 11

2.1 Overview 11

2.2 GBI Research Report Guidance 11

3 Global Men's Health Therapeutics Market: Market Characterization 12

3.1 Introduction 12

3.2 Market Forecasts 13

3.3 Annual Cost of Treatment 14

3.4 Treatment Usage Patterns 15

3.4.1 Diseased Population 17

3.4.2 Treatment Seeking Population 18

3.4.3 Diagnosis Population 19

3.4.4 Prescription Population 21

3.5 Market Share by Geography 22

3.6 Generics' Share in the Global Men's Health Market 23

3.7 Men's Health Market Drivers 24

3.7.1 Steady Increase in the Prevalence Population 24

3.7.2 Launch of late-stage pipeline candidates 24

3.7.3 Steady Increase in the Prescription Population 25

3.8 Men's Health Market Restraints 25

3.8.1 Low Treatment Seeking Rate 25

3.8.2 Low Diagnosis Rate 25

3.8.3 Patent Expiry of a Major Blockbuster 25

4 Global Erectile Dysfunction Therapeutics Market 26

4.1 Market Overview 26

4.2 Market Forecasts 27

4.3 Annual Cost of Treatment 28

4.4 Treatment Usage Patterns 29

4.4.1 Diseased Population 31

4.4.2 Treatment Seeking Population 32

4.4.3 Diagnosis Population 33

4.4.4 Prescription Population 35

4.5 Market Share by Geography 36

4.6 Product Analysis 37

4.6.1 Viagra (sildenafil citrate) 37

4.6.2 Cialis (tadalafil) 37

4.6.3 Levitra (verdenafil HCL) 37

4.6.4 Caverject (Alprostadil) 38

4.6.5 Muse (alprostadil) 38

5 Global Male Hypogonadism Therapeutics Market 39

5.1 Market Overview 39

5.2 Market Forecasts 40

5.3 Annual Cost of Treatment 41

5.4 Treatment Usage Patterns 42

5.4.1 Diseased Population 44

5.4.2 Treatment Seeking Population 45

5.4.3 Diagnosis Population 46

5.4.4 Prescription Population 48

5.5 Market Share by Geography 49

5.6 Product Analysis 50

5.6.1 Gel (AndroGel, Testim): 50

5.6.2 Injections (Depo-Testosterone, Delatestryl): 50

5.6.3 Transdermal Patch (Androderm, Testoderm) 50

5.6.4 Buccal Tablet (Striant) 50

5.6.5 Pellet Implant 50

6 Global Premature Ejaculation (PE) Therapeutics Market 51

6.1 Market Overview 51

6.2 Market Forecasts 51

6.3 Annual Cost of Treatment 53

6.4 Treatment Usage Patterns 54

6.4.1 Diseased Population 56

6.4.2 Treatment Seeking Population 57

6.4.3 Diagnosis Population 59

6.4.4 Prescription Population 60

6.5 Market Share by Geography 61

6.6 Product Analysis 62

6.6.1 Fluoxetine (Prozac, Sarafem) 62

6.6.2 Paroxetine (Paxil) 63

6.6.3 Sertraline (Zoloft) 63

6.6.4 Dapoxetine (Priligy) 63

6.6.5 Clomipramine (Anafranil) 63

6.6.6 Lidocaine/prilocaine cream (EMLA cream) 63

7 Global Men's Health Market: Geographical Landscape 64

7.1 Market Forecasts by Geography 64

7.2 The US 66

7.2.1 Market Forecasts 66

7.2.2 Annual Cost of Treatment 68

7.2.3 Treatment Usage Patterns 69

7.3 Top Five Countries in Europe 76

7.3.1 Market Forecasts 76

7.3.2 Annual Cost of Treatment 78

7.3.3 Treatment Usage Patterns 79

7.4 Japan 86

7.4.1 Market Forecasts 86

7.4.2 Annual Cost of Treatment 87

7.4.3 Treatment Usage Patterns 89

8 Global Men's Health Market: Pipeline Analysis 97

8.1 Introduction 97

8.1.1 Research and Development Pipeline – Erectile Dysfunction 99

8.1.2 Research and Development Pipeline – Premature Ejaculation 100

8.1.3 Research and Development Pipeline – Male Hypogonadism 101

8.2 Men's Health Pipeline – Pipeline by Clinical Phases of Development 102

8.2.1 Erectile Dysfunction Pipeline – Pipeline by Clinical Phases of Development 102

8.2.2 Premature Ejaculation Pipeline – Pipeline by Clinical Phases of Development 103

8.2.3 Male Hypogonadism Pipeline – Pipeline by Clinical Phases of Development 104

8.3 Profiles of Key Late-Stage Drugs in the Men's Health Market 106

8.3.1 Profiles of Key Late-Stage Drugs in the Erectile Dysfunction Market 106

8.3.2 Profiles of Key Late-Stage Drugs in the Premature Ejaculation Market 106

8.3.3 Profiles of Key Late-Stage Drugs in the Male Hypogonadism Market 107

9 Global Men's Health Market: Competitive Landscape 109

9.1 Overview 109

9.2 Competitive Profiling 109

9.2.1 Pfizer Inc. 109

9.2.2 Eli Lilly and Company 110

9.2.3 GlaxoSmithKline, Inc 111

9.2.4 Abbott Laboratories (Abbott acquired Solvay Pharmaceuticals) 112

9.2.5 Endo Pharmaceuticals Holding Inc. 113

9.2.6 Janssen-Cilag EMEA 114

9.2.7 VIVUS, Inc. 115

9.2.8 Auxilium Pharmaceuticals, Inc. 116

9.2.9 APP Pharmaceuticals (acquired by Fresenius Kabi Pharmaceuticals) 117

9.2.10 Columbia Laboratories, Inc. 118

9.2.11 Watson Pharmaceutical, Inc. 119

9.2.12 Valeant Pharmaceuticals International 120

10 Global Men's Health Market: Strategic Consolidations 122

10.1 Mergers and Acquisitions 122

10.1.1 Overview 122

10.1.2 Summary of Mergers and Acquisitions 125

10.2 R&D Licensing Agreements 128

10.2.1 Deals by Indication 128

10.2.2 Deals by Geography 129

10.2.3 Summary of Licensing Deals 129

11 Global Men's Health Therapeutics Market : Appendix 133

11.1 Market Definitions 133

11.2 Abbreviations 133

11.3 Research Methodology 134

11.3.1 Coverage 134

11.3.2 Secondary Research 134

11.3.3 Primary Research 134

11.3.4 Forecasts 135

11.3.5 Expert Panel Validation 137

11.4 Contact Us 138

11.5 Disclaimer 138

11.6 Sources 138

1.1 List of Tables

Table 1: Men's Health Therapeutics Market, Global, Revenue ($m), 2001–2009 13

Table 2: Men's Health Therapeutics Market, Global, Revenue ($m), 2009–2016 14

Table 3: Men's Health Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 14

Table 4: Men's Health Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 15

Table 5: Men's Health Therapeutics Market, Global, Usage Patterns, 2001–2009 16

Table 6: Men's Health Therapeutics Market, Global, Usage Patterns, 2009–2016 16

Table 7: Men's Health Therapeutics Market, Global, Diseased Population, 2001–2009 17

Table 8: Men's Health Therapeutics Market, Global, Diseased Population, 2009–2016 17

Table 9: Men's Health Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 18

Table 10: Men's Health Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 19

Table 11: Men's Health Therapeutics Market, Global, Diagnosis Population, 2001–2009 20

Table 12: Men's Health Therapeutics Market, Global, Diagnosis Population, 2009–2016 20

Table 13: Men's Health Therapeutics Market, Global, Prescription Population, 2001–2009 21

Table 14: Men's Health Therapeutics Market, Global, Prescription Population, 2009–2016 21

Table 15: Men's Health Therapeutics Market, Global, Market Drivers, 2010 24

Table 16: Men's Health Therapeutics Market, Global, Market Restraints, 2010 25

Table 17: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2001–2009 27

Table 18: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2009–2016 28

Table 19: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 28

Table 20: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 29

Table 21: Erectile Dysfunction Therapeutics Market, Global, Usage Patterns, 2001–2009 30

Table 22: Erectile Dysfunction Therapeutics Market, Global, Usage Patterns, 2009–2016 30

Table 23: Erectile Dysfunction Therapeutics Market, Global, Diseased Population, 2001–2009 31

Table 24: Erectile Dysfunction Therapeutics Market, Global, Diseased Population, 2009–2016 32

Table 25: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 33

Table 26: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 33

Table 27: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population, 2001–2009 34

Table 28: Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population, 2009–2016 34

Table 29: Erectile Dysfunction Therapeutics Market, Global, Prescription Population, 2001–2009 35

Table 30: Erectile Dysfunction Therapeutics Market, Global, Prescription Population, 2009–2016 35

Table 31: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2001–2009 40

Table 32: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2009–2016 40

Table 33: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 41

Table 34: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 42

Table 35: Male Hypogonadism Therapeutics Market, Global, Usage Patterns, 2001–2009 43

Table 36: Male Hypogonadism Therapeutics Market, Global, Usage Patterns, 2009–2016 43

Table 37: Male Hypogonadism Therapeutics Market, Global, Diseased Population, 2001–2009 44

Table 38: Male Hypogonadism Therapeutics Market, Global, Diseased Population, 2009–2016 44

Table 39: Male Hypogonadism Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 45

Table 40: Male Hypogonadism Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 46

Table 41: Male Hypogonadism Therapeutics Market, Global, Diagnosis Population, 2001–2009 47

Table 42: Male Hypogonadism Therapeutics Market, Global, Diagnosis Population, 2009–2016 47

Table 43: Male Hypogonadism Therapeutics Market, Global, Prescription Population, 2001–2009 48

Table 44: Male Hypogonadism Therapeutics Market, Global, Prescription Population, 2009–2016 48

Table 45: Premature Ejaculation Therapeutics Market, Global, Revenue ($m), 2001–2009 52

Table 46: Premature Ejaculation Therapeutics Market, Global, Revenue ($m), 2009–2016 52

Table 47: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2009 53

Table 48: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment ($), 2009–2016 53

Table 49: Premature Ejaculation Therapeutics Market, Global, Usage Patterns, 2001–2009 55

Table 50: Premature Ejaculation Therapeutics Market, Global, Usage Patterns, 2009–2016 55

Table 51: Premature Ejaculation Therapeutics Market, Global, Diseased Population, 2001–2009 56

Table 52: Premature Ejaculation Therapeutics Market, Global, Diseased Population, 2009–2016 56

Table 53: Premature Ejaculation Therapeutics Market, Global, Treatment Seeking Population, 2001–2009 58

Table 54: Premature Ejaculation Therapeutics Market, Global, Treatment Seeking Population, 2009–2016 58

Table 55: Premature Ejaculation Therapeutics Market, Global, Diagnosis Population, 2001–2009 59

Table 56: Premature Ejaculation Therapeutics Market, Global, Diagnosis Population, 2009–2016 59

Table 57: Premature Ejaculation Therapeutics Market, Global, Prescription Population, 2001–2009 61

Table 58: Premature Ejaculation Therapeutics Market, Global, Prescription Population, 2009–2016 61

Table 59: Men's Health Market, Global, Sales Value by Geography ($m), 2001–2009 64

Table 60: Men's Health Market, Global, Sales Value by Geography ($m), 2009–2016 65

Table 61: Men's Health Therapeutics Market, The US, Revenue ($m), 2001–2009 67

Table 62: Men's Health Therapeutics Market, The US, Revenue ($m), 2009–2016 67

Table 63: Men's Health Therapeutics Market, The US, Annual Cost of Treatment ($) , 2001–2009 68

Table 64: Men's Health Therapeutics Market, The US, Annual Cost of Treatment ($), 2009–2016 68

Table 65: Men's Health Therapeutics Market, The US, Usage Patterns, 2001–2009 70

Table 66: Men's Health Therapeutics Market, The US, Usage Patterns, 2009–2016 70

Table 67: Men's Health Therapeutics Market, The US, Diseased Population, 2001–2009 71

Table 68: Men's Health Therapeutics Market, The US, Diseased Population, 2009–2016 71

Table 69: Men's Health Therapeutics Market, The US, Treatment Seeking Population, 2001–2009 72

Table 70: Men's Health Therapeutics Market, The US, Treatment Seeking Population, 2009–2016 73

Table 71: Men's Health Therapeutics Market, The US, Diagnosis Population, 2001–2009 74

Table 72: Men's Health Therapeutics Market, The US, Diagnosis Population, 2009–2016 74

Table 73: Men's Health Therapeutics Market, The US, Prescription Population, 2001–2009 75

Table 74: Men's Health Therapeutics Market, The US, Prescription Population, 2009–2016 75

Table 75: Men's Health Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2001–2009 77

Table 76: Men's Health Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2009–2016 77

Table 77: Men's Health Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($) , 2001–2009 78

Table 78: Men's Health Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2009–2016 78

Table 79: Men's Health Therapeutics Market, Top Five Countries in Europe, Usage Patterns, 2001–2009 80

Table 80: Men's Health Therapeutics Market, Top Five Countries in Europe, Usage Patterns, 2009–2016 80

Table 81: Men's Health Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001–2009 81

Table 82: Men's Health Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2009–2016 81

Table 83: Men's Health Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001–2009 82

Table 84: Men's Health Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2009–2016 83

Table 85: Men's Health Therapeutics Market, Top Five Countries in Europe, Diagnosis Population, 2001–2009 84

Table 86: Men's Health Therapeutics Market, Top Five Countries in Europe, Diagnosis Population, 2009–2016 84

Table 87: Men's Health Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001–2009 85

Table 88: Men's Health Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2009–2016 85

Table 89: Men's Health Therapeutics Market, Japan, Revenue ($m), 2001–2009 86

Table 90: Men's Health Therapeutics Market, Japan, Revenue ($m), 2009–2016 87

Table 91: Men's Health Therapeutics Market, Japan, Annual Cost of Treatment , 2001–2009 88

Table 92: Men's Health Therapeutics Market, Japan, Annual Cost of Treatment, 2009–2016 88

Table 93: Men's Health Therapeutics Market, Japan, Usage Patterns, 2001–2009 90

Table 94: Men's Health Therapeutics Market, Japan, Usage Patterns, 2009–2016 90

Table 95: Men's Health Therapeutics Market, Japan, Diseased Population, 2001–2009 91

Table 96: Men's Health Therapeutics Market, Japan, Diseased Population, 2009–2016 91

Table 97: Men's Health Therapeutics Market, Japan, Treatment Seeking Population, 2001–2009 92

Table 98: Men's Health Therapeutics Market, Japan, Treatment Seeking Population, 2009–2016 93

Table 99: Men's Health Therapeutics Market, Japan, Diagnosis Population, 2001–2009 94

Table 100: Men's Health Therapeutics Market, Japan, Diagnosis Population, 2009–2016 94

Table 101: Men's Health Therapeutics Market, Japan, Prescription Population, 2001–2009 95

Table 102: Men's Health Therapeutics Market, Japan, Prescription Population, 2009–2016 96

Table 103: Erectile Dysfunction Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 102

Table 104: Erectile Dysfunction Therapeutics –Phase II Clinical Pipeline, 2010 102

Table 105: Erectile Dysfunction Therapeutics –Phase I Clinical Pipeline, 2010 103

Table 106: Erectile Dysfunction Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 103

Table 107: Premature Ejaculation Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 103

Table 108: Premature Ejaculation Therapeutics –Phase II Clinical Pipeline, 2010 104

Table 109: Premature Ejaculation Therapeutics –Phase I Clinical Pipeline, 2010 104

Table 110: Premature Ejaculation Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 104

Table 111: Male Hypogonadism Therapeutics –Regulatory Filing and Phase III Clinical Pipeline, 2010 104

Table 112: Male Hypogonadism Therapeutics –Phase II Clinical Pipeline, 2010 105

Table 113: Male Hypogonadism Therapeutics –Phase I Clinical Pipeline, 2010 105

Table 114: Male Hypogonadism Therapeutics – Preclinical and Discovery Clinical Pipeline, 2010 105

Table 115: Eli Lilly and Company – Men's Health Pipeline Products, 2010 111

Table 116: GlaxoSmithKline, Inc – Men's Health Pipeline Products, 2010 112

Table 117: Abbott Laboratories– Men's Health Pipeline Products, 2010 113

Table 118: Endo Pharmaceuticals Holding Inc. – Men's Health Pipeline Products, 2010 114

Table 119: VIVUS, Inc. – Men's Health Pipeline Products, 2010 116

Table 120: Watson Pharmaceuticals, Inc. – Men's Health Pipeline Products, 2010 120

1.2 List of Figures

Figure 1: Men's Health Therapeutics Market, Global, Drivers and Restraints, 2009 12

Figure 2: Men's Health Therapeutics Market, Global, Revenue ($m), 2001-2016 13

Figure 3: Men's Health Therapeutics Market, Global, Annual Cost of Treatment ($), 2001–2016 14

Figure 4: Men's Health Therapeutics Market, Global, Treatment Usage Patterns, 2001-2016 15

Figure 5: Men's Health Therapeutics Market, Global, Diseased Population, 2001-2016 17

Figure 6: Men's Health Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 18

Figure 7: Men's Health Therapeutics Market, Global, Diagnosis Population, 2001-2016 19

Figure 8: Men's Health Therapeutics Market, Global, Prescription Population, 2001-2016 21

Figure 9: Men's Health Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 22

Figure 10: Men's Health Therapeutic Market, Global, Branded v/s Generic Drugs, 2009 23

Figure 11: Erectile Dysfunction Therapeutics Market, Global, Revenue ($m), 2001-2016 27

Figure 12: Erectile Dysfunction Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 28

Figure 13: Erectile Dysfunction Therapeutics Market, Global, Treatment Usage Patterns, 2001-2016 29

Figure 14: Erectile Dysfunction Therapeutics Market, Global, Diseased Population, 2001-2016 31

Figure 15: Erectile Dysfunction Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 32

Figure 16:Erectile Dysfunction Therapeutics Market, Global, Diagnosis Population, 2001-2016 34

Figure 17: Erectile Dysfunction Therapeutics Market, Global, Prescription Population, 2001-2016 35

Figure 18: Erectile Dysfunction Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 36

Figure 19: Male Hypogonadism Therapeutics Market, Global, Revenue ($m), 2001-2016 40

Figure 20: Male Hypogonadism Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 41

Figure 21: Male Hypogonadism Therapeutics Market, Global, Usage Patterns, 2001-2016 42

Figure 22: Male Hypogonadism Therapeutics Market, Global, Diseased Population, 2001-2016 44

Figure 23: Male Hypogonadism Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 45

Figure 24: Male Hypogonadism Therapeutics Market, Global, Diagnosis Population, 2001-2016 46

Figure 25: Male Hypogonadism Therapeutics Market, Global, Prescription Population, 2001-2016 48

Figure 26: Male Hypogonadism Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 49

Figure 27: Premature Ejaculation Therapeutics Market, Global, Revenue ($m), 2001-2016 52

Figure 28: Premature Ejaculation Therapeutics Market, Global, Annual Cost of Treatment ($), 2001-2016 53

Figure 29: Premature Ejaculation Therapeutics Market, Global, Usage Patterns, 2001-2016 54

Figure 30: Premature Ejaculation Therapeutics Market, Global, Diseased Population, 2001-2016 56

Figure 31: Premature Ejaculation Therapeutics Market, Global, Treatment Seeking Population, 2001-2016 57

Figure 32: Premature Ejaculation Therapeutics Market, Global, Diagnosis Population, 2001-2016 59

Figure 33: Premature Ejaculation Therapeutics Market, Global, Prescription Population, 2001-2016 60

Figure 34: Premature Ejaculation Therapeutic Market, Global, Market Share by Geography, 2009 and 2016 62

Figure 35: Men's Health Market, Global, Market Forecasts by Geography ($m), 2001–2016 64

Figure 36: Men's Health Market, Global, Geography Benchmarking, 2009 and 2016 65

Figure 37: Men's Health Therapeutics Market, The US, Revenue ($m), 2001-2016 66

Figure 38: Men's Health Therapeutics Market, The US, Annual Cost of Treatment ($), 2001-2016 68

Figure 39: Men's Health Therapeutics Market, The US, Usage Patterns, 2001-2016 69

Figure 40: Men's Health Therapeutics Market, The US, Diseased Population, 2001-2016 71

Figure 41: Men's Health Therapeutics Market, The US, Treatment Seeking Population, 2001-2016 72

Figure 42: Men's Health Therapeutics Market, The US, Diagnosis Population, 2001-2016 73

Figure 43: Men's Health Therapeutics Market, The US, Prescription Population, 2001-2016 75

Figure 44: Men's Health Therapeutics Market, Top Five Countries in Europe, Revenue ($m), 2001-2016 76

Figure 45: Men's Health Therapeutics Market, Top Five Countries in Europe, Annual Cost of Treatment ($), 2001-2016 78

Figure 46: Men's Health Therapeutics Market, Top Five Countries in Europe, Usage Patterns, 2001-2016 79

Figure 47: Men's Health Therapeutics Market, Top Five Countries in Europe, Diseased Population, 2001-2016 81

Figure 48: Men's Health Therapeutics Market, Top Five Countries in Europe, Treatment Seeking Population, 2001-2016 82

Figure 49: Men's Health Therapeutics Market, Top Five Countries in Europe, Diagnosis Population, 2001-2016 83

Figure 50: Men's Health Therapeutics Market, Top Five Countries in Europe, Prescription Population, 2001-2016 85

Figure 51: Men's Health Therapeutics Market, Japan, Revenue ($m), 2001-2016 86

Figure 52: Men's Health Therapeutics Market, Japan, Annual Cost of Treatment, 2001-2016 87

Figure 53: Men's Health Therapeutics Market, Japan, Usage Patterns, 2001-2016 89

Figure 54: Men's Health Therapeutics Market, Japan, Diseased Population, 2001-2016 91

Figure 55: Men's Health Therapeutics Market, Japan, Treatment Seeking Population, 2001-2016 92

Figure 56: Men's Health Therapeutics Market, Japan, Diagnosis Population, 2001-2016 94

Figure 57: Men's Health Therapeutics Market, Japan, Prescription Population, 2001-2016 95

Figure 58: Men's Health Market, Global, R&D Pipeline by Indication (%), 2010 97

Figure 59: Men's Health Market, Global, R&D Pipeline by Phase (%), 2010 98

Figure 60: Men's Health Market, Global, R&D Pipeline by Phase in Erectile Dysfunction (%), 2010 99

Figure 61: Men's Health Market, Global, R&D Pipeline by Phase in Premature Ejaculation Market (%), 2010 100

Figure 62: Men's Health, Global, R&D Pipeline by Phase in Male Hypogonadism (%), 2010 101

Figure 63: Pfizer Inc., SWOT Analysis, 2010 110

Figure 64: Eli Lilly and Company, SWOT Analysis, 2010 111

Figure 65: GlaxoSmithKline, Inc, SWOT Analysis, 2010 112

Figure 66: Abbott Laboratories, SWOT Analysis, 2010 113

Figure 67: Endo Pharmaceuticals Holding Inc, SWOT Analysis, 2010 114

Figure 68: Janssen-Cilag EMEA, SWOT Analysis, 2010 115

Figure 69: VIVUS Inc., SWOT Analysis, 2010 116

Figure 70: Auxilium Pharmaceuticals, Inc, SWOT Analysis, 2010 117

Figure 71: APP Pharmaceuticals, Inc, SWOT Analysis, 2010 118

Figure 72: Columbia Laboratories, Inc., SWOT Analysis, 2010 119

Figure 73: Watson Pharmaceuticals, Inc., SWOT Analysis, 2010 120

Figure 74: Valeant Pharmaceuticals International, SWOT Analysis, 2010 121

Figure 75: Men's Health Market, Global, M&A Deals by Indication (%), 2010 122

Figure 76: Men's Health Market, Global, M&A Deals by Value, $m, (%), 2010 123

Figure 77: Men's Health Market, Global, M&A Deals by Geography, (%), 2010 124

Figure 78: Men's Health Market, Global, M&A Deals by Type, (%), 2010 125

Figure 79: Men's Health Market, Global, Major Licensing Agreements By Indication (%), 2010 128

Figure 80: Men's Health Market, Global, Major Licensing Agreements By Geography (%), 2010 129

Figure 81: GBI Research Market Forecasting Methodology, 2010 137

Companies mentioned

Pfizer Inc.

Eli Lilly and Company

GlaxoSmithKline, Inc

Abbott Laboratories (Abbott acquired Solvay Pharmaceuticals)

Endo Pharmaceuticals Holding Inc.

Janssen-Cilag EMEA

VIVUS, Inc.

Auxilium Pharmaceuticals, Inc.

APP Pharmaceuticals (acquired by Fresenius Kabi Pharmaceuticals)

Columbia Laboratories, Inc.

Watson Pharmaceutical, Inc.

Valeant Pharmaceuticals International

To order this report:

Pathology Industry:

Pathology Business News

More  Market Research Report

Check our  Company Profile, SWOT and Revenue Analysis!

Contact:

Nicolas Bombourg

Reportlinker

Email: nbo@reportlinker.com

US: (805)652-2626

Intl: +1 805-652-2626



SOURCE Reportlinker



RELATED LINKS

http://www.reportlinker.com